Page 67 - 《中国药房》2026年10期

analysis of antiretroviral drugs for treatment-naive HIV in‐ a cost-effectiveness analysis for the United States[J]. Phar‐
fection in China[J]. BMC Public Health，2023，23（1）： macoEconomics，2013，31（5）：427-444.
2228. [19] RESTELLI U，RIZZARDINI G，ANTINORI A，et al.
[ 7 ] PIALOUX G，MARCELIN A G，CAWSTON H，et al. Cost-effectiveness analysis of dolutegravir plus backbone
Cost-effectiveness of dolutegravir/abacavir/lamivudine in compared with raltegravir plus backbone，darunavir+rito‐
HIV-1 treatment-naive（TN）patients in France[J]. Expert navir plus backbone and efavirenz/tenofovir/emtricitabine
Rev Pharmacoeconomics Outcomes Res，2018，18（1）： in treatment naïve and experienced HIV-positive patients
83-91. [J]. Ther Clin Risk Manag，2017，13：787-797.
[ 8 ] ZHANG H J，KONG Y H，CHEN H T，et al. The cost- [20] ORKIN C，SQUIRES K E，MOLINA J M，et al. Dora‐
effectiveness analysis of single-tablet efavirenz-based regi‐ virine/lamivudine/tenofovir disoproxil fumarate （TDF）
men among HIV-1 infected adults in China[J]. Front Pub‐ versus efavirenz/emtricitabine/TDF in treatment-naive adults
lic Health，2025，13：1429461. with human immunodeficiency virus type 1 infection：
[ 9 ] 国家卫生健康委员会 . 2024 年我国卫生健康事业发展 week 96 results of the randomized，double-blind，phase 3
统 计 公 报 [EB/OL].（2025-12-02）[2026-02-04]. https：// DRIVE-AHEAD noninferiority trial[J]. Clin Infect Dis，
www.nhc.gov.cn/guihuaxxs/c100133/202512/f1c3a3c6174 2021，73（1）：33-42.
84a27a1a26a468afbaeee/files/2024%E5%B9%B4%E6%8- [21] MURPHY R L，DA SILVA B A，HICKS C B，et al. Seven-
8%91%E5%9B% BD% E5%8D% AB% E7%94%9F% E5%- year efficacy of a lopinavir/ritonavir-based regimen in
81%A5%E5%BA%B7%E4%BA%8B%E4%B8%9A%E- antiretroviral-naïve HIV-1-infected patients[J]. HIV Clin
5%8F%91%E5%B1%95%E7%BB%9F%E8%AE%A1%- Trials，2008，9（1）：1-10.
E5%85%AC%E6%8A%A5-20251201161542231.pdf. [22] HUANG Y Q，HUANG X J，LUO Y D，et al. Assessing
[10] VANDEWALLE B，LLIBRE J M，PARIENTI J J，et al. the efficacy of lopinavir/ritonavir-based preferred and al‐
EPICE-HIV：an epidemiologic cost-effectiveness model ternative second-line regimens in HIV-infected patients：a
for HIV treatment[J]. PLoS One，2016，11（2）：e0149007. meta-analysis of key evidence to support WHO recom‐
[11] 中国疾病预防控制中心艾防中心. 《国家免费艾滋病抗 mendations[J]. Front Pharmacol，2018，9：890.
病毒药物治疗手册（2023 年版）》正式发布[EB/OL]. [23] CHIVITE I，BERROCAL L，DE LAZZARI E，et al. Effec‐
（2023-06-13）[2026-02-04]. https：//ncaids. chinacdc. cn/ tiveness，safety and discontinuation rates of bictegravir/
zxzx/zxdteff/202306/t20230616_266839.htm. emtricitabine/tenofovir alafenamide （BIC/FTC/TAF） in
[12] WU X S，WU G H，MA P，et al. Associations of modern people with HIV using real-world data：a systematic re‐
initial antiretroviral therapy regimens with all-cause mor‐ view and meta-analysis[J]. J Antimicrob Chemother，
tality in people living with HIV in resource-limited set‐ 2024，79（8）：1775-1783.
tings：a retrospective multicenter cohort study in China[J]. [24] KANTERS S，VITORIA M，DOHERTY M，et al. Com‐
Nat Commun，2023，14：5334. parative efficacy and safety of first-line antiretroviral
[13] 白洁，张弨. 比克恩丙诺在获得性免疫缺陷综合征治疗 therapy for the treatment of HIV infection：a systematic re‐
中的应用及研究新进展[J]. 临床药物治疗杂志，2021，19 view and network meta-analysis[J]. Lancet HIV，2016，3
（3）：20-25. （11）：e510-e520.
[14] 国家统计局 . 中国统计年鉴 2024[DB/OL].（2024-10-25） [25] MOLINA J M，CAHN P，GRINSZTEJN B，et al. Rilpi-
[2026-02-04]. https：//www. stats. gov. cn/sj/ndsj/2024/ind‐ virine versus efavirenz with tenofovir and emtricitabine in
exch.htm. treatment-naive adults infected with HIV-1（ECHO）：a
[15] GIROUARD M P，SAX P E，PARKER R A，et al. The phase 3 randomised double-blind active-controlled trial[J].
cost-effectiveness and budget impact of 2-drug Lancet，2011，378（9787）：238-246.
dolutegravir-lamivudine regimens for the treatment of [26] 彭新雨. 艾滋病抗病毒治疗纳入医保的可行性研究[D].
HIV infection in the United States[J]. Clin Infect Dis， 北京：中国疾病预防控制中心，2018.
2016，62（6）：784-791. [27] AI W，FAN C X，MARLEY G，et al. Disparities in health‐
[16] PENG S Y，TAFAZZOLI A，DORMAN E，et al. Cost- care access and utilization among people living with HIV
effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC in China：a scoping review and meta-analysis[J]. HIV
for first-line treatment of HIV-1 in the United States[J]. J Med，2023，24（11）：1093-1105.
Int AIDS Soc，2014，17（4S3）：19605. [28] WANG X L，YAN C Y，TONG Y S，et al. Comparison of
[17] GUILLÉN S M，GARCÍA J E L，BERENGUER J B，et al. psycho-social factors associated with suicidal ideation and
Cost-utility analysis of the fixed-dose combination of do‐ suicide attempts among people living with HIV in central
lutegravir/abacavir/lamivudine as initial treatment of HIV+ west China[J]. Front Public Health，2022，10：832624.
patients in Spain[J]. Farm Hosp，2017，41（5）：601-610. （收稿日期：2026-01-13 修回日期：2026-05-12）
[18] SIMPSON K N，PEI P P，MÖLLER J，et al. Lopinavir/ （编辑：孙 冰）
ritonavir versus darunavir plus ritonavir for HIV infection：

中国药房 2026年第37卷第10期 China Pharmacy 2026 Vol. 37 No. 10 · 1301 ·